## **AMENDMENTS**

## In the Specification:

Please replace the original specification with the substitute specification submitted on May 2, 2005 (a copy is enclosed herewith).

Please replace the paragraph at page 3, lines 15-25 of the substitute specification submitted on May 2, 2005 with the following substitute paragraph:

Because of the suitability of peptide/peptide interactions in promoting conformational changes, peptidomimetics are a preferred class of non-peptide molecules which may make up the library screened in accordance with a method of the invention. The design and production of peptidomimetics is now well known in the art and the skilled man is aware of how such molecules may be prepared and screened. Many pharmaceutical and other companies have their own banks of peptidomimetics and other organic compounds which could be used in the in vivo screening methods of the present invention. The following website provides details of a number of Examples of suppliers of compound libraries[[,]] such as include Advanced Chemtech, Affymax, **BioLeads** GmbH. ComGenexm etc[[.,]] and Inc. http://www.htscreening.net/suppliers/comblib.html.

Please replace the paragraph at page 18, line 34 to page 19, line 26 of the substitute specification submitted on May 2, 2005 with the following substitute paragraph:

## **Materials and Methods**

pCEP4 (Invitrogen):

TTGACG<u>CAAA T</u>GGGCGGTAG GCGTGTACGG TGGGAGGTC<u>T ATATAA</u>GC<u>AG</u>
CAAT
TATA

AGCTCGTTTA GTGAACCGTC AGATCTCTAG AAGCTGGGTA CCAGCTGCTA
pCEP Forward primer KpnI

GCAAGCTTGC TAGCGGCCGC TCGAGGCCGG CAAGGCCGGA TCCAGACATG HindIII

ATAAGATACA TT<u>GATGAGTT TGGACAAACC AC</u>AACTAGAA (SEQ. ID. NO.: 4)
EBV Reverse primer

Oligo REGP-10:							
5'-AAGAGCTC <u>GG TACC</u> AAG	AAG GAGTTTAC	AT ATO	G GGA	NNK	NNK	NNK	TGA
KpnI		M	G	X	X	X	stop
TAA GGATCC <u>AAG CTT</u> GAAT	TTCA G-3' (SEQ. I	ID. NO.:	(5)				
Stop HindIII							
Oligo REGP-11:							
5'-AAGAGCTC <u>GGTACC</u> AAGA	AAGGAG-3' (SEQ.	. ID. NO	0.: 6)				
KpnI							
Oligo REGP-12:							
5' -CTGAATTC <u>AAGCTT</u> GGAT	CCTTATC-3' (SE	Q. ID. N	IO.: 7)	ı			
HindIII							
pCEP Forward primer: 5' -AGAGCTCGTTTAGTGAAC	CCG-3' (SEQ. ID. 1	NO.: 8)					
EBV Reverse primer:							
5' -GTGGTTTGTCCAAACTCA	TC-3' (SEQ. ID. N	(O.: 9)					
Please replace the paragraph at p	page 22, lines 7-13	of the si	ıbstitui	te spec	ificatio	n subi	nitted on
May 2, 2005 with the following su	ubstitute paragraph	:					
DNA: 5'- <u>GGTACC</u> AAGAAGGA	AGTTTACAT <b>ATG</b>	GGA T	GG T	GT A	CT TG	A TA	A

KpnI

DNA: GGATCC<u>AAGCTT</u>-3' (SEQ. ID. NO.: 10) HindIII

Amino acid:

M G W C T stop stop